Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
O.G. Melikhov, Tatiana S. Кruglova, K. Lytkina, G.G. Melkonyan, Е. А. Прохорович, Gleb A. Putsman, Г. В. Родоман, Arkady Vertkin, А. I. Zagrebneva, Justin Stebbing
Abstract
Table 1 Clinical outcomes in patients with COVID-19 treated with tofacitinib All cases <65 years old >65 years old Population Number of patents, n (%) 320 (100) 210 (66) 110 (34) Female, % 50 46 57 Mean age (range), years 59 (22-96) 52 (22-64) 74 (65-96) Mean treatment duration (range), days 7 (1-18) 6 (1-17) 7 (1-18) Dexamethasone, % 30.0 30.0 30.0 Disease (on admission) Clinical severity, % Mild 4.7 3.8 6.4
Topics & Concepts
MedicineObservational studyCoronavirus disease 2019 (COVID-19)Janus kinase2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TofacitinibSeries (stratigraphy)VirologyInternal medicineDiseaseOutbreakRheumatoid arthritisCytokinePaleontologyInfectious disease (medical specialty)BiologyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchDrug-Induced Hepatotoxicity and Protection